Eli Lilly upgrades full-year guidance due to solid growth in Q1

US-based pharmaceutical firm Eli Lilly has adjusted its revenue projection for the full year, with the new outlook of USD 28.8–29.3bn.
Photo: Mike Segar/Reuters/Ritzau Scanpix
Photo: Mike Segar/Reuters/Ritzau Scanpix
by marketwire, translated by daniel pedersen

US-based Eli Lilly is upgrading its 2022 revenue outlook in connection with the company’s first quarterly report on Thursday.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading